{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:54:13Z","timestamp":1791554053919,"version":"4.3.4"},"reference-count":97,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA266342"],"award-info":[{"award-number":["CA266342"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA272946"],"award-info":[{"award-number":["CA272946"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myeloid-derived suppressor cells are a pivotal component of the immunosuppressive tumor microenvironment in hematologic malignancies. Through diverse mechanisms, they promote disease progression, therapeutic resistance, and immune evasion. This comprehensive review synthesizes current evidence on the roles of myeloid-derived suppressor cells across major hematologic cancers and evaluates their prognostic significance, highlighting implications for patient stratification and potential therapeutic targeting.<\/jats:p>","DOI":"10.1093\/jimmun\/vkag249","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:38:42Z","timestamp":1791553122000},"source":"Crossref","is-referenced-by-count":0,"title":["Myeloid-derived suppressor cells in hematologic malignancies: A current state of the field"],"prefix":"10.1093","volume":"215","author":[{"given":"Yulia","family":"Nefedova","sequence":"first","affiliation":[{"name":"Ellen and Ronald Caplan Cancer Center, Wistar Institute , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry I","family":"Gabrilovich","sequence":"additional","affiliation":[{"name":"ICC, Oncology R&D, AstraZeneca , Gaithersburg, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2026100909383632500_vkag249-B1","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"2026100909383632500_vkag249-B2","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1038\/s44318-026-00829-6","article-title":"Human immunosuppressive neutrophils: Recent answers to old and new questions","volume":"45","author":"Scapini","year":"2026","journal-title":"EMBO J"},{"key":"2026100909383632500_vkag249-B3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201803","article-title":"Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice","volume":"218","author":"Veglia","year":"2021","journal-title":"J Exp Med"},{"key":"2026100909383632500_vkag249-B4","doi-asserted-by":"publisher","first-page":"aaf8943","DOI":"10.1126\/sciimmunol.aaf8943","article-title":"Lectin-type oxidized ldl receptor 1 defines population of polymorphonuclear myeloid-derived suppressor cells in cancer patients","volume":"1","author":"Condamine","year":"2016","journal-title":"Sci Immunol."},{"key":"2026100909383632500_vkag249-B5","doi-asserted-by":"publisher","first-page":"101380","DOI":"10.1016\/j.xcrm.2023.101380","article-title":"Surface cd52, cd84, and ptger2 mark mature pmn-mdscs from cancer patients and g-csf-treated donors","volume":"5","author":"Pettinella","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026100909383632500_vkag249-B6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10555-025-10278-y","article-title":"Metastasis-promoting functions of myeloid cells","volume":"44","author":"Kusmartsev","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"2026100909383632500_vkag249-B7","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1158\/2159-8290.CD-21-0764","article-title":"Myeloid-derived suppressor cells: a propitious road to clinic","volume":"11","author":"Grover","year":"2021","journal-title":"Cancer Discov"},{"key":"2026100909383632500_vkag249-B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.smim.2017.12.004","article-title":"Neutrophils and pmn-mdsc: Their biological role and interaction with stromal cells","volume":"35","author":"Zhou","year":"2018","journal-title":"Semin Immunol"},{"key":"2026100909383632500_vkag249-B9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"2026100909383632500_vkag249-B10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2026100909383632500_vkag249-B11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1189\/jlb.5MA1116-453RR","article-title":"Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor b cell acute lymphoblastic leukemia","volume":"102","author":"Liu","year":"2017","journal-title":"J Leukoc Biol"},{"key":"2026100909383632500_vkag249-B12","doi-asserted-by":"publisher","first-page":"15039","DOI":"10.1038\/s41598-021-94469-x","article-title":"Increase in polymorphonuclear myeloid-derived suppressor cells and regulatory t-cells in children with b-cell acute lymphoblastic leukemia","volume":"11","author":"Zahran","year":"2021","journal-title":"Sci Rep"},{"key":"2026100909383632500_vkag249-B13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/08923973.2018.1424897","article-title":"Chemotherapy alters the increased numbers of myeloid-derived suppressor and regulatory t cells in children with acute lymphoblastic leukemia","volume":"40","author":"Salem","year":"2018","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2026100909383632500_vkag249-B14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1365-2141.2011.08902.x","article-title":"Association of an increased frequency of cd14+ hla-dr lo\/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (cll)","volume":"156","author":"Gustafson","year":"2012","journal-title":"Br J Haematol"},{"key":"2026100909383632500_vkag249-B15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"Cll-cells induce idohi cd14\u2009+\u2009hla-drlo myeloid-derived suppressor cells that inhibit t-cell responses and promote Tregs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"2026100909383632500_vkag249-B16","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3892\/ol.2014.2808","article-title":"Cd14(+)hla-dr(low\/-) expression: A novel prognostic factor in chronic lymphocytic leukemia","volume":"9","author":"Liu","year":"2015","journal-title":"Oncol Lett"},{"key":"2026100909383632500_vkag249-B17","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.3390\/ijms20215459","article-title":"Monocytic myeloid derived suppressor cells in hematological malignancies","volume":"20","author":"Palumbo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026100909383632500_vkag249-B18","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41375-021-01249-7","article-title":"Myeloid-derived suppressor cell subtypes differentially influence t-cell function, t-helper subset differentiation, and clinical course in cll","volume":"35","author":"Ferrer","year":"2021","journal-title":"Leukemia"},{"key":"2026100909383632500_vkag249-B19","volume-title":"Leukemia","author":"Li","year":"2022"},{"key":"2026100909383632500_vkag249-B20","first-page":"9:7007","article-title":"Immunosuppressive role of cd11b(+) cd33(+) hla-dr(-) myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia","author":"Hyun","year":"2020","journal-title":"Cancer Med"},{"key":"2026100909383632500_vkag249-B21","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","article-title":"Muc1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood"},{"key":"2026100909383632500_vkag249-B22","doi-asserted-by":"publisher","first-page":"2554167","DOI":"10.1155\/jimr\/2554167","article-title":"Detection of monocyte subsets in the bone marrow of patients with acute myeloid leukemia and its clinical significance","volume":"2025","author":"Zhang","year":"2025","journal-title":"J Immunol Res"},{"key":"2026100909383632500_vkag249-B23","doi-asserted-by":"publisher","first-page":"200719","DOI":"10.7754\/Clin.Lab.2020.200719","article-title":"Increased levels of circulating monocytic- and early-stage myeloid-derived suppressor cells (mdsc) in acute myeloid leukemia","volume":"67","author":"Lv","year":"2021","journal-title":"Clin Lab"},{"key":"2026100909383632500_vkag249-B24","doi-asserted-by":"publisher","first-page":"7363084","DOI":"10.1155\/2020\/7363084","article-title":"Circulating monocytic myeloid-derived suppressor cells are elevated and associated with poor prognosis in acute myeloid leukemia","volume":"2020","author":"Wang","year":"2020","journal-title":"J Immunol Res"},{"key":"2026100909383632500_vkag249-B25","doi-asserted-by":"publisher","first-page":"108821","DOI":"10.1016\/j.intimp.2022.108821","article-title":"Abnormal immune function of mdsc and nk cells from chronic phase cml patients restores with tyrosine kinase inhibitors","volume":"109","author":"Hong","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2026100909383632500_vkag249-B26","doi-asserted-by":"publisher","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","article-title":"Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble cd25 in sokal high risk chronic myeloid leukemia","volume":"8","author":"Christiansson","year":"2013","journal-title":"PLoS One"},{"key":"2026100909383632500_vkag249-B27","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/jcmm.13326","article-title":"Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib","volume":"22","author":"Giallongo","year":"2018","journal-title":"J Cell Mol Med"},{"key":"2026100909383632500_vkag249-B28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3343\/alm.2021.41.5.479","article-title":"Granulocytic and monocytic myeloid-derived suppressor cells are functionally and prognostically different in patients with chronic myeloid leukemia","volume":"41","author":"Ahn","year":"2021","journal-title":"Ann Lab Med"},{"key":"2026100909383632500_vkag249-B29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.13198","article-title":"Circulating myeloid-derived suppressor cells correlate with clinical outcome in hodgkin lymphoma patients treated up-front with a risk-adapted strategy","volume":"168","author":"Romano","year":"2015","journal-title":"Br J Haematol"},{"key":"2026100909383632500_vkag249-B30","doi-asserted-by":"publisher","first-page":"27676","DOI":"10.18632\/oncotarget.8507","article-title":"Identification of granulocytic myeloid-derived suppressor cells (g-mdscs) in the peripheral blood of hodgkin and non-hodgkin lymphoma patients","volume":"7","author":"Marini","year":"2016","journal-title":"Oncotarget"},{"key":"2026100909383632500_vkag249-B31","doi-asserted-by":"publisher","first-page":"9232540","DOI":"10.1155\/jimr\/9232540","article-title":"Myeloid-derived suppressor cells (mdscs) suppress t-cell proliferation less than mature neutrophils in blood and bone marrow from multiple myeloma patients","volume":"2026","author":"Westerlund","year":"2026","journal-title":"J Immunol Res"},{"key":"2026100909383632500_vkag249-B32","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2010-05-283820","article-title":"Immunosuppressive cd14\u2009+\u2009hla-dr(low)\/- monocytes in b-cell non-Hodgkin lymphoma","volume":"117","author":"Lin","year":"2011","journal-title":"Blood"},{"key":"2026100909383632500_vkag249-B33","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/jleuko\/qiae032","article-title":"Accumulation of circulating myeloid-derived suppressor cell subsets: Predicting poor clinical efficacy and prognosis through t cell suppression in non-Hodgkin\u2019s lymphoma","volume":"115","author":"Pu","year":"2024","journal-title":"J Leukoc Biol"},{"key":"2026100909383632500_vkag249-B34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12885-019-5529-0","article-title":"Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients","volume":"19","author":"Amini","year":"2019","journal-title":"BMC Cancer"},{"key":"2026100909383632500_vkag249-B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.25259\/Cytojournal_165_2024","article-title":"Association of immunosuppressive cd45(+)cd33(+)cd14(-) cd10(-)hla-dr(-\/low) neutrophils with poor prognosis in patients with lymphoma and their expansion and activation through stat3\/arginase-1 pathway in vitro","volume":"21","author":"Xiao","year":"2024","journal-title":"Cytojournal"},{"key":"2026100909383632500_vkag249-B36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/imcb.12728","article-title":"Cd14(-)cd10(-)cd45(+)hla-dr(-)ssc(+) neutrophils may be granulocytic myeloid-derived suppressor cell-like cells and relate to disease progression in non-Hodgkin\u2019s lymphoma patients","volume":"102","author":"Zhou","year":"2024","journal-title":"Immunol Cell Biol"},{"key":"2026100909383632500_vkag249-B37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00277-026-06797-5","article-title":"Elevated circulating cd10(-) granulocytic myeloid-derived suppressor cells correlate with disease activity and poor prognosis in patients with diffuse large b-cell lymphoma","volume":"105","author":"Li","year":"2026","journal-title":"Ann Hematol"},{"key":"2026100909383632500_vkag249-B38","doi-asserted-by":"publisher","first-page":"104125","DOI":"10.1016\/j.exphem.2023.10.004","article-title":"Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large b cell lymphoma treated with chemoimmunotherapy","volume":"129","author":"Foureau","year":"2024","journal-title":"Exp Hematol"},{"key":"2026100909383632500_vkag249-B39","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting t cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J Immunol"},{"key":"2026100909383632500_vkag249-B40","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"key":"2026100909383632500_vkag249-B41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-019-1011-5","article-title":"Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing pirna-823 expression and dnmt3b activation","volume":"18","author":"Ai","year":"2019","journal-title":"Mol Cancer"},{"key":"2026100909383632500_vkag249-B42","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2026100909383632500_vkag249-B43","doi-asserted-by":"publisher","first-page":"85764","DOI":"10.18632\/oncotarget.7969","article-title":"Granulocyte-like myeloid derived suppressor cells (g-mdsc) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (msc)","volume":"7","author":"Giallongo","year":"2016","journal-title":"Oncotarget"},{"key":"2026100909383632500_vkag249-B44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/14737159.2018.1470929","article-title":"Pmn-mdsc and arginase are increased in myeloma and may contribute to resistance to therapy","volume":"18","author":"Romano","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"2026100909383632500_vkag249-B45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-3083.2010.02463.x","article-title":"Increased level of both cd4\u2009+\u2009foxp3+ regulatory t cells and cd14\u2009+\u2009hla-dr\u207b\/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma","volume":"72","author":"Brimnes","year":"2010","journal-title":"Scand J Immunol"},{"key":"2026100909383632500_vkag249-B46","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.3390\/jcm10204717","article-title":"Increased monocytic myeloid-derived suppressor cells in whole blood predict poor prognosis in patients with plasma cell myeloma","volume":"10","author":"Bae","year":"2021","journal-title":"J Clin Med"},{"key":"2026100909383632500_vkag249-B47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.141683","article-title":"Cd84 is a regulator of the immunosuppressive microenvironment in multiple myeloma","volume":"6","author":"Lewinsky","year":"2021","journal-title":"JCI Insight"},{"key":"2026100909383632500_vkag249-B48","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14737140.2025.2483855","article-title":"Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (aml) and myelodysplastic syndrome (mds) tumor microenvironment","volume":"25","author":"Alhajahjeh","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026100909383632500_vkag249-B49","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1172\/JCI67580","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest"},{"key":"2026100909383632500_vkag249-B50","doi-asserted-by":"publisher","first-page":"e1062208","DOI":"10.1080\/2162402X.2015.1062208","article-title":"Expansion of myeloid derived suppressor cells correlates with number of t regulatory cells and disease progression in myelodysplastic syndrome","volume":"5","author":"Kittang","year":"2016","journal-title":"Oncoimmunology."},{"key":"2026100909383632500_vkag249-B51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-3-031-26163-3_15","article-title":"Increase in frequency of myeloid-derived suppressor cells in the bone marrow of myeloproliferative neoplasm: potential implications in myelofibrosis","volume":"1408","author":"Kapor","year":"2023","journal-title":"Adv Exp Med Biol"},{"key":"2026100909383632500_vkag249-B52","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41577-018-0008-4","article-title":"Clocking in to immunity","volume":"18","author":"Scheiermann","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2026100909383632500_vkag249-B53","doi-asserted-by":"publisher","first-page":"loaf018","DOI":"10.1093\/lifemeta\/loaf018","article-title":"Circadian metabolism in myeloid cells","volume":"4","author":"Xu","year":"2025","journal-title":"Life Metab."},{"key":"2026100909383632500_vkag249-B54","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.immuni.2018.10.007","article-title":"Circadian expression of migratory factors establishes lineage-specific signatures that guide the homing of leukocyte subsets to tissues","volume":"49","author":"He","year":"2018","journal-title":"Immunity"},{"key":"2026100909383632500_vkag249-B55","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1182\/blood-2018-10-844571","article-title":"Neutrophils as regulators of the hematopoietic niche","volume":"133","author":"Coss\u00edo","year":"2019","journal-title":"Blood"},{"key":"2026100909383632500_vkag249-B56","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.it.2019.03.010","article-title":"Time-of-day-dependent trafficking and function of leukocyte subsets","volume":"40","author":"Pick","year":"2019","journal-title":"Trends Immunol"},{"key":"2026100909383632500_vkag249-B57","doi-asserted-by":"publisher","first-page":"102255","DOI":"10.1016\/j.isci.2021.102255","article-title":"Seasonal and daytime variation in multiple immune parameters in humans: evidence from 329,261 participants of the UK biobank cohort","volume":"24","author":"Wyse","year":"2021","journal-title":"iScience"},{"key":"2026100909383632500_vkag249-B58","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3389\/fimmu.2020.00576","article-title":"Circadian features of neutrophil biology","volume":"11","author":"Aroca-Crevill\u00e9n","year":"2020","journal-title":"Front Immunol"},{"key":"2026100909383632500_vkag249-B59","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1139\/y02-121","article-title":"Circadian variation in cell-adhesion molecule expression by normal human leukocytes","volume":"80","author":"Niehaus","year":"2002","journal-title":"Can J Physiol Pharmacol"},{"key":"2026100909383632500_vkag249-B60","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1126\/science.1240636","article-title":"Circadian gene bmal1 regulates diurnal oscillations of ly6c(hi) inflammatory monocytes","volume":"341","author":"Nguyen","year":"2013","journal-title":"Science"},{"key":"2026100909383632500_vkag249-B61","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/s41467-017-02111-0","article-title":"Loss of the molecular clock in myeloid cells exacerbates t cell-mediated cns autoimmune disease","volume":"8","author":"Sutton","year":"2017","journal-title":"Nat Commun"},{"key":"2026100909383632500_vkag249-B62","doi-asserted-by":"publisher","first-page":"e2200031","DOI":"10.1002\/adbi.202200031","article-title":"Circadian rhythm disruption increases tumor growth rate and accumulation of myeloid-derived suppressor cells","volume":"6","author":"Roberts","year":"2022","journal-title":"Adv Biol (Weinh)"},{"key":"2026100909383632500_vkag249-B63","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41590-024-01859-0","article-title":"Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade","volume":"25","author":"Fortin","year":"2024","journal-title":"Nat Immunol"},{"key":"2026100909383632500_vkag249-B64","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41375-018-0360-1","article-title":"Immune cell constitution in bone marrow microenvironment predicts outcome in adult all","volume":"33","author":"Hohtari","year":"2019","journal-title":"Leukemia"},{"key":"2026100909383632500_vkag249-B65","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1111\/jcmm.17576","article-title":"Peripheral levels of monocytic myeloid-derived suppressive cells before and after first induction predict relapse and survivals in aml patients","volume":"26","author":"Peterlin","year":"2022","journal-title":"J Cell Mol Med"},{"key":"2026100909383632500_vkag249-B66","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4274\/tjh.galenos.2022.2022.0137","article-title":"Monocytic myeloid-derived suppressor cells but not monocytes predict poor prognosis of acute myeloid leukemia","volume":"39","author":"Ren","year":"2022","journal-title":"Turk J Haematol"},{"key":"2026100909383632500_vkag249-B67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12026-024-09558-6","article-title":"Prognostic value of myeloid-derived suppressor-like cells in acute myeloid leukemia: insights from immunophenotyping and clinical correlations","volume":"73","author":"Sant\u2019Ana","year":"2024","journal-title":"Immunol Res"},{"key":"2026100909383632500_vkag249-B68","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00262-020-02656-y","article-title":"Cd66b(+) monocytes represent a proinflammatory myeloid subpopulation in cancer","volume":"70","author":"Horzum","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2026100909383632500_vkag249-B69","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1002\/iid3.616","article-title":"Elevated circulating myeloid-derived suppressor cells associated with poor prognosis in b-cell non-Hodgkin\u2019s lymphoma patients","volume":"10","author":"Wang","year":"2022","journal-title":"Immun Inflamm Dis."},{"key":"2026100909383632500_vkag249-B70","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3390\/jcm10081768","article-title":"Elevated m-mdscs in circulation are indicative of poor prognosis in diffuse large b-cell lymphoma patients","volume":"10","author":"Wang","year":"2021","journal-title":"J Clin Med"},{"key":"2026100909383632500_vkag249-B71","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000445644","article-title":"Prognostic significance of monocytes and monocytic myeloid-derived suppressor cells in diffuse large b-cell lymphoma treated with r-chop","volume":"39","author":"Wu","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"2026100909383632500_vkag249-B72","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with car t-cell failure in large b-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"2026100909383632500_vkag249-B73","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00262-016-1861-2","article-title":"Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory\/relapsed multiple myeloma","volume":"65","author":"Lee","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2026100909383632500_vkag249-B74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10238-025-01986-4","article-title":"Mdsc subpopulation dynamics predict disease evolution: A multidimensional biomarker framework for risk assessment in mds","volume":"26","author":"Hu","year":"2026","journal-title":"Clin Exp Med"},{"key":"2026100909383632500_vkag249-B75","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.smim.2021.101515","article-title":"G-csf, the guardian of granulopoiesis","volume":"54","author":"Mehta","year":"2021","journal-title":"Semin Immunol"},{"key":"2026100909383632500_vkag249-B76","doi-asserted-by":"publisher","first-page":"104147","DOI":"10.1016\/j.exphem.2023.104147","article-title":"G-csf-induced hematopoietic stem cell mobilization from the embryonic hematopoietic niche does not require neutrophils and macrophages","volume":"131","author":"Kim","year":"2024","journal-title":"Exp Hematol"},{"key":"2026100909383632500_vkag249-B77","doi-asserted-by":"publisher","first-page":"155479","DOI":"10.1016\/j.cyto.2021.155479","article-title":"G-csf in tumors: aggressiveness, tumor microenvironment and immune cell regulation","volume":"142","author":"Karagiannidis","year":"2021","journal-title":"Cytokine"},{"key":"2026100909383632500_vkag249-B78","doi-asserted-by":"publisher","first-page":"e27690","DOI":"10.1371\/journal.pone.0027690","article-title":"Tumor-derived g-csf facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism","volume":"6","author":"Waight","year":"2011","journal-title":"PloS One"},{"key":"2026100909383632500_vkag249-B79","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clim.2012.01.011","article-title":"G-csf stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells","volume":"143","author":"Luyckx","year":"2012","journal-title":"Clin Immunol"},{"key":"2026100909383632500_vkag249-B80","doi-asserted-by":"publisher","first-page":"220436","DOI":"10.7754\/Clin.Lab.2022.220436","article-title":"Impact of rhg-csf on clinical efficacy and immune cell subsets after initial induction chemotherapy in aml","volume":"69","author":"Zhou","year":"2023","journal-title":"Clin Lab"},{"key":"2026100909383632500_vkag249-B81","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3390\/jcm14041254","article-title":"Use of primary prophylaxis with g-csf in acute myeloid leukemia patients undergoing intensive chemotherapy does not affect quality of response","volume":"14","author":"Mezzanotte","year":"2025","journal-title":"J Clin Med"},{"key":"2026100909383632500_vkag249-B82","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4103\/njcp.njcp_607_24","article-title":"The effects of adding g-csf to the induction therapy of patients with aml being treated with the 7\u2009+\u20093 protocol: A retrospective comparative study","volume":"28","author":"Eser","year":"2025","journal-title":"Niger J Clin Pract"},{"key":"2026100909383632500_vkag249-B83","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/bjh.15801","article-title":"Immune off-target effects of brentuximab vedotin in relapsed\/refractory hodgkin lymphoma","volume":"185","author":"Romano","year":"2019","journal-title":"Br J Haematol"},{"key":"2026100909383632500_vkag249-B84","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1158\/1078-0432.CCR-22-0588","article-title":"Lenalidomide plus r-gdp (r2-gdp) in relapsed\/refractory diffuse large b-cell lymphoma: Final results of the r2-gdp-gotel trial and immune biomarker subanalysis","volume":"28","author":"Palaz\u00f3n-Carri\u00f3n","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026100909383632500_vkag249-B85","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1038\/s41467-024-47096-9","article-title":"Myeloid-derived suppressor cell mitochondrial fitness governs chemotherapeutic efficacy in hematologic malignancies","volume":"15","author":"Daneshmandi","year":"2024","journal-title":"Nat Commun"},{"key":"2026100909383632500_vkag249-B86","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.16881","article-title":"Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma","volume":"191","author":"Kuwahara-Ota","year":"2020","journal-title":"Br J Haematol"},{"key":"2026100909383632500_vkag249-B87","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cei.12343","article-title":"Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients","volume":"177","author":"Busch","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2026100909383632500_vkag249-B88","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/2326-6066.CIR-13-0213","article-title":"Targeting immune suppression with pde5 inhibition in end-stage multiple myeloma","volume":"2","author":"Noonan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2026100909383632500_vkag249-B89","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1182\/blood-2010-06-287839","article-title":"Bone marrow myeloid-derived suppressor cells (mdscs) inhibit graft-versus-host disease (gvhd) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13","volume":"116","author":"Highfill","year":"2010","journal-title":"Blood"},{"key":"2026100909383632500_vkag249-B90","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3389\/fimmu.2020.00989","article-title":"Myeloid-derived suppressor cells in the context of allogeneic hematopoietic stem cell transplantation","volume":"11","author":"D\u2019Aveni","year":"2020","journal-title":"Front Immunol"},{"key":"2026100909383632500_vkag249-B91","doi-asserted-by":"publisher","first-page":"73","DOI":"10.15283\/ijsc18094","article-title":"Predictive role of circulating immune cell subtypes early after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia","volume":"12","author":"Kim","year":"2018","journal-title":"Int J Stem Cells"},{"key":"2026100909383632500_vkag249-B92","doi-asserted-by":"publisher","first-page":"101074","DOI":"10.1016\/j.ctarc.2025.101074","article-title":"Hematologic malignancies and an overview of emerging therapies for hematologic malignancies: a systematic review","volume":"46","author":"Ghaffari","year":"2026","journal-title":"Cancer Treat Res Commun"},{"key":"2026100909383632500_vkag249-B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011768","article-title":"Acquisition of an immunosuppressive microenvironment after anti-cd19 car t-cell therapy is associated with t-cell dysfunction and resistance","volume":"13","author":"Ponzo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026100909383632500_vkag249-B94","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"Car t therapies in multiple myeloma: Unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"2026100909383632500_vkag249-B95","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1182\/bloodadvances.2024014345","article-title":"Bcma-directed car t-cell therapy in patients with multiple myeloma and cns involvement","volume":"9","author":"Gaballa","year":"2025","journal-title":"Blood Adv"},{"key":"2026100909383632500_vkag249-B96","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1080\/08923973.2025.2585083","article-title":"Functional role of granulocytic myeloid-derived suppressor cells in car-t therapy: Insights from single-cell RNA sequencing in multiple myeloma","volume":"47","author":"Zhang","year":"2025","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2026100909383632500_vkag249-B97","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s43018-026-01159-6","article-title":"Harnessing myeloid cell plasticity for cancer therapy","volume":"7","author":"Sanseviero","year":"2026","journal-title":"Nat Cancer"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/215\/10\/vkag249\/71787821\/vkag249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/215\/10\/vkag249\/71787821\/vkag249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:38:44Z","timestamp":1791553124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/doi\/10.1093\/jimmun\/vkag249\/8898613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":97,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jimmun\/vkag249","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]},"article-number":"vkag249"}}